

Corp. Off.: **Orchid Pharma Ltd.**, 'Orchid Towers' 313, Valluvarkottam High Road, Nungambakkam, Chennai - 600 034. India.

March 30, 2022

**CIN: L24222TN1992PLC022994**

<b>National Stock Exchange of India Limited</b> Listing Department Exchange Plaza, 5th Floor, Plot No: C/1, G - Block, Bandra — Kurla Complex, Bandra (East), Mumbai - 400 051 NSE Symbol: ORCHPHARMA	<b>BSE Limited</b> Corporate Relationship Department 1st floor, New Trading Ring Rotunda Building, P J Towers Dalal Street, Fort Mumbai - 400 001 BSE Code: 524372
---	---

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Intimation regarding receipt of Observation letters from the National Stock Exchange of India Limited and BSE Limited in relation to the proposed Scheme of Amalgamation and Arrangement between Dhanuka Laboratories Limited ('Transferor Company') and Orchid Pharma Limited ( 'Transferee Company' ) and their respective shareholders and creditors ('Scheme')**

Sir/Madam

This is in continuation to our earlier communication submitted to your good office on December 16, 2021, wherein it was intimated that the Board of Directors of Orchid Pharma Limited had approved the Scheme of Amalgamation and Arrangement between Dhanuka Laboratories Limited and Orchid Pharma Limited and their respective shareholders and creditors under Section 230 to 232 read with other applicable provisions of the Companies Act, 2013 and Rules framed thereunder subject to the receipt of applicable regulatory approvals.

Further in compliance with the provisions of Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we would like to inform you that the National Stock Exchange of India Limited and BSE Limited have issued their Observation /No-objection Letters dated March 29, 2022 and March 30, 2022 respectively as required under Regulation 37 of the Listing Regulations conveying 'No adverse observation/ No-objection' to the proposed Scheme (copies attached).


The copies of the aforesaid observation/No objection letters are enclosed. The aforesaid letters are also hosted on the website of the Company at [www.orchidpharma.com](http://www.orchidpharma.com).

Kindly take the above information on records.

Thanking you

Yours faithfully,

For: **Orchid Pharma Limited**

  
Nikita K  
Company Secretary

Encl: a/a

**National Stock Exchange Of India Limited**

Ref: NSE/LIST/29553\_III

March 29, 2022

The Company Secretary  
Orchid Pharma Limited  
Orchid Towers, 313, Valluvarkottam High Road,  
Nugambakkam, Chennai – 600034.

**Kind Attn.: Ms. Nikita K**

Dear Madam,

**Sub: Observation Letter for draft scheme of amalgamation and arrangement of Dhanuka Laboratories Limited with Orchid Pharma Limited and their respective shareholders and creditors**

We are in receipt of draft scheme of amalgamation and arrangement of Dhanuka Laboratories Limited (“Amalgamating Company”) with Orchid Pharma Limited (“Amalgamated Company”) and their respective shareholders and creditors vide application dated December 29, 2021.

Based on our letter reference no. NSE/LIST/29553 dated January 19, 2022 submitted to SEBI and pursuant to SEBI Circular No. CFD/DIL3/CIR/2017/21 dated March 10, 2017 (“Circular”), kindly find following comments on the draft scheme:

- a. *Company shall ensure that additional information, if any, submitted by the Company after filing the Scheme with the Stock Exchange, from the date of receipt of this letter is displayed on the websites of the listed company and the Stock Exchanges.*
- b. *The Company shall duly comply with various provisions of the Circular.*
- c. *Company is advised that the observations of SEBI/Stock Exchanges shall be incorporated in the petition to be filed before National Corporate Law Tribunal (NCLT) and the company is obliged to bring the observations to the notice of NCLT.*
- d. *It is to be noted that the petitions are filed by the Company before NCLT after processing and communication of comments/observations on draft scheme by SEBI/Stock Exchanges. Hence, the company is not required to send notice for representation as mandated under Section 230(5) of Companies Act, 2013 to SEBI again for its comments/ observations/ representations.*

**It is to be noted that the petitions are filed by the company before NCLT after processing and communication of comments/observations on draft scheme by SEBI/ stock exchange. Hence, the company is not required to send notice for representation as mandated under section 230(5) of Companies Act, 2013 to National Stock Exchange of India Limited again for its comments/observations/representations.**

The Document is Digitally Signed

Further, where applicable in the explanatory statement of the notice to be sent by the company to the shareholders, while seeking approval of the scheme, it shall disclose information about unlisted companies involved in the format prescribed for abridged prospectus as specified in the Circular.

Based on the draft scheme and other documents submitted by the Company, including undertaking given in terms of Regulation 11 of SEBI (LODR) Regulations, 2015, we hereby convey our “No objection” in terms of Regulation 94 of SEBI (LODR) Regulations, 2015, so as to enable the Company to file the draft scheme with NCLT.

However, the Exchange reserves its rights to raise objections at any stage if the information submitted to the Exchange is found to be incomplete/ incorrect/ misleading/ false or for any contravention of Rules, Bye-laws and Regulations of the Exchange, Listing Regulations, Guidelines/ Regulations issued by statutory authorities.

The validity of this “Observation Letter” shall be six months from March 29, 2022 within which the scheme shall be submitted to NCLT.

**The Company shall ensure filing of compliance status report stating the compliance with each point of Observation Letter on draft scheme of arrangement on the following path: NEAPS > Issue > Scheme of arrangement > Reg 37(1) of SEBI LODR, 2015> Seeking Observation letter to Compliance Status.**

Yours faithfully,  
For National Stock Exchange of India Limited

Harshad Dharod  
Manager

P.S. Checklist for all the Further Issues is available on website of the exchange at the following URL:  
<https://www.nseindia.com/companies-listing/raising-capital-further-issues-main-sme-checklist>

This Document is Digitally Signed

DCS/AMAL/TL/IP/2281/2021-22

“E-Letter”

March 30, 2022

The Company Secretary,  
**Orchid Pharma Ltd**  
313, Orchid Towers, Valluvar kottam  
High Road, Nungambakkum, Chennai,  
Tamil Nadu, 600034

Dear Sir,

**Sub: Observation letter regarding the Scheme of Amalgamation and Arrangement of Dhanuka Laboratories Limited with Orchid Pharma Limited and their respective Shareholders and Creditors**

We are in receipt of the Draft Scheme of Amalgamation and Arrangement of Dhanuka Laboratories Limited with Orchid Pharma Limited and their respective Shareholders and Creditors as required under SEBI Circular No. CFD/DIL3/CIR/2017/21 dated March 10, 2017; SEBI vide its letter dated March 29, 2022, has inter alia given the following comment(s) on the draft scheme of Amalgamation and Arrangement:

- **“Company shall ensure that additional information and undertakings, if any submitted by the Company, after filing the Scheme with the Stock Exchange, and from the date of receipt of this letter is displayed on the websites of the listed Company and the Stock Exchanges.”**
- **“Company shall ensure compliance with the said Circular.”**
- **“Company shall ensure that the observations of SEBI/Stock Exchanges shall be incorporated in the petition to be filed before Hon'ble National Company Law Tribunal (NCLT) and the Company obliged to bring the observations to the notice of Hon'ble NCLT.”**
- **“It is to be noted that the petitions are filed by the Company before Hon'ble NCLT after processing and communication of comments/observations on draft Scheme by SEBI/Stock Exchange. Hence, the Company is not required to send notice for representation as mandated under section 230(5) of Companies Act, 2013 to SEBI again for its comments/observations/representations.”**

Accordingly, based on aforesaid comment offered by SEBI, the company is hereby advised:

- To provide additional information, if any, (as stated above) along with various documents to the Exchange for further dissemination on Exchange website.
- To ensure that additional information, if any, (as stated aforesaid) along with various documents are disseminated on their (company) website.
- To duly comply with various provisions of the circulars.

In light of the above, we hereby advise that we have no adverse observations with limited reference to those matters having a bearing on listing/de-listing/continuous listing requirements within the provisions of Listing Agreement, so as to enable the company to file the scheme with Hon'ble NCLT.

Further, where applicable in the explanatory statement of the notice to be sent by the company to the shareholders, while seeking approval of the scheme, it shall disclose information about unlisted company involved in the format prescribed for abridged prospectus as specified in the circular dated March 10, 2017.

Kindly note that as required under Regulation 37(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the validity of this Observation Letter shall be six months from the date of this Letter, within which the scheme shall be submitted to the NCLT.

The Exchange reserves its right to withdraw its 'No adverse observation' at any stage if the information submitted to the Exchange is found to be incomplete / incorrect / misleading / false or for any contravention of Rules, Bye-laws and Regulations of the Exchange, Listing Agreement, Guidelines/Regulations issued by statutory authorities. Please note that the aforesaid observations does not preclude the Company from complying with any other requirements.

Further, it may be noted that with reference to Section 230 (5) of the Companies Act, 2013 (Act), read with Rule 8 of Companies (Compromises, Arrangements and Amalgamations) Rules 2016 (Company Rules) and Section 66 of the Act read with Rule 3 of the Company Rules wherein pursuant to an Order passed by the Hon'ble National Company Law Tribunal, a Notice of the proposed scheme of compromise or arrangement filed under sections 230-232 or Section 66 of the Companies Act 2013 as the case may be **is required to be served upon the Exchange seeking representations or objections if any.**

In this regard, with a view to have a better transparency in processing the aforesaid notices served upon the Exchange, the Exchange has **already introduced an online system of serving such Notice along with the relevant documents of the proposed schemes through the BSE Listing Centre.**

Any service of notice under Section 230 (5) or Section 66 of the Companies Act 2013 seeking Exchange's representations or objections if any, **would be accepted and processed through the Listing Centre only and no physical filings would be accepted.** You may please refer to circular dated February 26, 2019 issued to the company.

Yours faithfully,

Sd/-  
**Prasad Bhide**  
Manager